NGS as the First-line Treatment in Advanced Biliary Tract Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

December 27, 2019

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Advanced Biliary Tract Cancer
Interventions
DRUG

TS-1

Intervention is administered to patients in this Arm.

DRUG

Gemcitabine

Intervention is administered to patients in this Arm.

DRUG

Nivolumab

Intervention is administered to patients in this Arm.

Trial Locations (6)

Unknown

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City

Chang Gung Memorial Hospital, Linkou District

China Medical University Hospital, Taichung

National Cheng Kung University Hospital, Tainan City

National Taiwan University Hospital, Taipei

Taipei Veterans General Hospital, Taipei

All Listed Sponsors
collaborator

Taipei Veterans General Hospital, Taiwan

OTHER_GOV

collaborator

Chang Gung Memorial Hospital

OTHER

collaborator

China Medical University Hospital

OTHER

collaborator

National Cheng-Kung University Hospital

OTHER

collaborator

Kaohsiung Medical University Chung-Ho Memorial Hospital

OTHER

collaborator

National Taiwan University Hospital

OTHER

lead

National Health Research Institutes, Taiwan

OTHER

NCT04172402 - NGS as the First-line Treatment in Advanced Biliary Tract Cancer | Biotech Hunter | Biotech Hunter